IDegLira success in Phase III trial for Type 2 Diabetes

Phase III data from the investigational therapy IDegLira [Tresiba (insulin degludec)/Victoza (liraglutide injection)] from Novo Nordisk,were presented at the 49th Annual European Association for the Study of Diabetes (EASD) Congress. Data from the DUALT I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone, with no weight gain and a low rate of hypoglycaemia compared to insulin degludec in adults with Type 2 Diabetes. These results were also supported by data showing once-daily IDegLira provides statistically greater reductions in postprandial glucose following all three main meals of the day (breakfast, lunch and dinner) compared to insulin degludec.

IDegLira is a once-daily, single-administration basal insulin/GLP-1 analogue combination being developed for the treatment of Type 2 Diabetes in adults.

See- Gough SCL, et al. "IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial."- Oral presentation (OP 37) at the 49th Annual European Association for the Study of Diabetes (EASD) Congress, 27 September 2013.